In this episode of Beyond the Scale: The Ozempic Effect, hosts Terry Turner and Christian Simmons explore the high cost of GLP-1 medications like Ozempic and Wegovy — and why many Americans still can’t afford them. Former Congressman Robert Andrews, a key architect of the Affordable Care Act and now CEO of the Health Transformation Alliance, explains why these medications remain so expensive and what it would take to bring prices down. Pharmacist and Liviniti co-founder Dr. Steven Boyd takes listeners behind the scenes of the drug pricing system, shedding light on the role pharmacy benefit managers (PBMs) play in driving up costs — and how employers are pushing back to make coverage more transparent and affordable. Clinical pharmacist Dr. Elizabeth Van Dril returns to discuss the risks of compounded GLP-1 drugs, often sold at lower prices but without FDA approval or consistent quality. If you’re wondering who gets access to these life-changing medications — and why — this episode breaks it down.Learn more at Drugwatch.com.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
Buchladen: Tipps für Weihnachten
20 Dec 2025
eat.READ.sleep. Bücher für dich
BOJ alza 25pb decennale sopra 2%, Oracle vola con accordo Tik Tok, 90 mld eurobond per Ucraina | Morning Finance
19 Dec 2025
Black Box - La scatola nera della finanza
365. The BEST advice for managing ADHD in your 20s ft. Chris Wang
19 Dec 2025
The Psychology of your 20s
LVST 19 de diciembre de 2025
19 Dec 2025
La Venganza Será Terrible (oficial)
Cuando la Ciencia Ficción Explicó el Mundo que Hoy Vivimos
19 Dec 2025
El Podcast de Marc Vidal